Last reviewed · How we verify

NCT05806554

Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial

Completed Last updated 25 November 2025
What this trial tests

trial testing Continuous glucose monitoring device in Diabetes Mellitus in 159 participants. Completed in 22 October 2024.

Timeline
19 July 2023
Primary endpoint
13 June 2024
22 October 2024

Quick facts

Lead sponsorSinocare
StatusCompleted
Study typeOBSERVATIONAL
Enrollment159
Start date19 July 2023
Primary completion13 June 2024
Estimated completion22 October 2024
Sites6 locations across United States, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Sinocare

Who can join

Adults 18 to 80, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Performance of a New Continuous Glucose Monitoring System in German Adults Living with Diabetes.
    Jendrike N, Link M, Öter S, Fei J, et al · · 2026 · PMID 41461989 · DOI 10.1007/s13300-025-01832-6

Verify or expand the search:

Other trials of Continuous glucose monitoring device

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Sinocare trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05806554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing